The crucial relationship between vancomycin minimum inhibitory concentration and therapeutic efficacy against methicillin-resistant coagulase-negative staphylococci

被引:1
作者
Niinuma, Yusuke [1 ]
Kagami, Keisuke [1 ]
Sugawara, Mitsuru [1 ,2 ]
Takekuma, Yoh [1 ]
机构
[1] Hokkaido Univ Hosp, Dept Pharm, Kita 14 Jo,Nishi 5 Chome,Kita Ku, Sapporo 0608648, Japan
[2] Hokkaido Univ, Fac Pharmaceut Sci, Div Pharmasci, Sapporo, Japan
关键词
Vancomycin; methicillin-resistant coagulase-negative staphylococci; methicillin-resistant Staphylococcus aureus; therapeutic drug monitoring; area under the curve; minimum inhibitory concentration; INFECTIOUS-DISEASES SOCIETY; CLINICAL-PRACTICE GUIDELINES; BLOOD-STREAM INFECTIONS; AUREUS INFECTIONS; BACTEREMIA; AMERICA;
D O I
10.1080/1120009X.2024.2394326
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The area under the curve (AUC)/minimum inhibitory concentration (MIC) ratio was used as an indicator of the clinical efficacy of vancomycin. However, the target AUC/MIC has not been set for methicillin-resistant coagulase-negative staphylococci (MR-CNS), and the effectiveness of vancomycin in strains with high MIC is unknown. Therefore, we aimed to investigate the relationship between the vancomycin MIC and therapeutic efficacy in patients with MR-CNS bacteremia. The primary outcome was the difference in treatment failure rate when the MR-CNS vancomycin MIC was 1 or 2 mu g/mL. The treatment failure rate did not significantly differ between the two groups (MIC 1 vs. MIC 2: 27.0% vs. 31.0%; p = 0.779). As a result of multivariate analysis, AUC/MIC0-24 h <= 230 was extracted as risk factor for treatment failure, suggesting the importance of a sufficient initial loading dose and early blood concentration monitoring to increase AUC/MIC0-24 h for successful treatment.
引用
收藏
页码:326 / 333
页数:8
相关论文
共 33 条
[1]   Association between Vancomycin Day 1 Exposure Profile and Outcomes among Patients with Methicillin-Resistant Staphylococcus aureus Infective Endocarditis [J].
Casapao, Anthony M. ;
Lodise, Thomas P. ;
Davis, Susan L. ;
Claeys, Kimberly C. ;
Kullar, Ravina ;
Levine, Donald P. ;
Rybak, Michael J. .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2015, 59 (06) :2978-2985
[2]   Optimal exposure targets for vancomycin in the treatment of neonatal coagulase-negative Staphylococcus infection: A retrospective study based on electronic medical records [J].
Chen, Quanyao ;
Wan, Jun ;
Shen, Wei ;
Lin, Wanlong ;
Lin, Xiuxian ;
Huang, Zhiyi ;
Lin, Min ;
Chen, Yao .
PEDIATRICS AND NEONATOLOGY, 2022, 63 (03) :247-254
[3]   Relationship between the MIC of vancomycin and clinical outcome in patients with MRSA nosocomial pneumonia [J].
Choi, Eun Young ;
Huh, Jin Won ;
Lim, Chae-Man ;
Koh, Younsuck ;
Kim, Sung-Han ;
Choi, Sang-Ho ;
Kim, Yang Soo ;
Kim, Mi-Na ;
Hong, Sang-Bum .
INTENSIVE CARE MEDICINE, 2011, 37 (04) :639-647
[4]   Combination antibiotic therapy versus monotherapy for gram-negative bacteraemia: a commentary [J].
Chow, JW ;
Yu, VL .
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 1999, 11 (01) :7-12
[5]  
Clinical and Laboratory Standard Institute, 2023, Performance standards for antimicrobial susceptibility testing
[6]   Vancomycin dosage optimization in patients with malignant haematological disease by pharmacokineticpharmacodynamic analysis [J].
Gatta M.D.M.F.D. ;
Buelga D.S. ;
Navarro A.S. ;
Dominguez-Gil A. ;
García M.J. .
Clinical Pharmacokinetics, 2009, 48 (4) :273-280
[7]   Clinical Significance of a Single Staphylococcus lugdunensis-Positive Blood Culture [J].
Fadel, Hind J. ;
Patel, Robin ;
Vetter, Emily A. ;
Baddour, Larry M. .
JOURNAL OF CLINICAL MICROBIOLOGY, 2011, 49 (04) :1697-1699
[8]  
Finch NA, 2017, ANTIMICROB AGENTS CH, V61, DOI [10.1128/AAC.01293-17, 10.1128/aac.01293-17]
[9]   Clinical and epidemiologic significance of coagulase-negative staphylococci bacteremia in a tertiary care university Israeli hospital [J].
Finkelstein, R ;
Fusman, R ;
Oren, I ;
Kassis, I ;
Hashman, N .
AMERICAN JOURNAL OF INFECTION CONTROL, 2002, 30 (01) :21-25
[10]   Risk factors for hematogenous complications of intravascular catheter-associated Staphylococcus aureus Bacteremia [J].
Fowler, VG ;
Justice, A ;
Moore, C ;
Benjamin, DK ;
Woods, CW ;
Campbell, S ;
Reller, LB ;
Corey, GR ;
Day, NPJ ;
Peacock, SJ .
CLINICAL INFECTIOUS DISEASES, 2005, 40 (05) :695-703